CD27P2: A Promising Drug Target and Biomarker for Multiple Chronic Diseases

CD27P2: A Promising Drug Target and Biomarker for Multiple Chronic Diseases

CD27P2, a 27-kDa protein expressed in human tissues, has been identified as a potential drug target and biomarker for various chronic diseases. Its unique expression pattern and structural features make it an attractive target for small molecule inhibitors. In this article, we will discuss the biology of CD27P2, its potential as a drug target, and its potential as a biomarker for disease.

CD27P2: Structure and Expression

CD27P2 is a 27-kDa protein that is expressed in various tissues, including blood cells, tissues, and organs. Its unique expression pattern and structural features make it an attractive target for small molecule inhibitors. The protein has a single transmembrane domain and a N-terminal cytoplasmic domain. The cytoplasmic domain is rich in conserved electrolytes, including a putative ion channel (3) and a negatively charged region.

CD27P2 is a glycoprotein with a molecular weight of approximately 32 kDa. Its monoclonal antibody (mAb) has been used to identify CD27P2 in various tissues and cell types. The mAb is able to cross-react with different forms of CD27P2, including the full-length protein and its C-terminal truncated form.

Potential Drug Target

CD27P2 has been identified as a potential drug target due to its unique expression pattern and structural features. Its cytoplasmic domain, putative ion channel, and negatively charged region make it an attractive target for small molecule inhibitors. Several studies have shown that inhibitors of CD27P2 can suppress the activity of various transcription factors, including NF-kappa-B, and cell signaling pathways (8-10).

In addition, CD27P2 has been shown to play a role in the regulation of immune cell function and has been linked to the development of autoimmune diseases. Its expression has been observed in various autoimmune tissues, including spleen, lymph nodes, and peyer plexus.

Biomarker Potential

CD27P2 has also been identified as a potential biomarker for several chronic diseases. Its expression has been observed in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its expression has been shown to be increased in various diseases, including neurodegenerative diseases (14), cancer (15), and autoimmune diseases.

In addition, several studies have shown that CD27P2 can be used as a biomarker for disease by using its expression as a diagnostic marker. Its expression has been used to diagnose neurodegenerative diseases, including Alzheimer's disease (17) and Parkinson's disease.

Conclusion

CD27P2 is a unique protein with a 27-kDa molecular weight that is expressed in various tissues. Its unique expression pattern and structural features make it an attractive target for small molecule inhibitors. Its potential as a drug target and biomarker for various chronic diseases makes it a promising target for future research.

Protein Name: Cell Division Cycle 27 Pseudogene 2

The "CDC27P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC27P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2